Cholesterol, Alzheimer's Disease, Prion disorders: A ménage à trois?

Current Drug Targets

Volumn 11, Issue 8, 2010, Pages 1018-1031

  Pani, Alessandra ^a   Mandas, Antonella ^a   Dessì, Sandra ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Alzheimer's disease; Cholesterol esters; Lipid rafts; Modulators of cholesterol homeostasis; Plasma membrane; Prion disorders; Protein misfolding diseases

Indexed keywords

3 DECYLDIMETHYLSILYL N [2 (4 METHYLPHENYL) 1 PHENYLETHYL]PROPIONAMIDE; AMYLOID; AMYLOID BETA PROTEIN; AVASIMIBE; CHLORPROMAZINE; CHOLESTEROL; CHOLESTEROL ESTER; CP 113818; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LIPOPROTEIN; MEPACRINE; PIOGLITAZONE; PROGESTERONE; UNCLASSIFIED DRUG; VERAPAMIL;

ALZHEIMER DISEASE; ARTICLE; BETA SHEET; CYTOTOXICITY; DISEASE ASSOCIATION; HOMEOSTASIS; HUMAN; LIPID RAFT; NONHUMAN; PATHOPHYSIOLOGY; PRION DISEASE; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEIN STRUCTURE; ANIMAL; CELL MEMBRANE; METABOLISM; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CELL MEMBRANE; CHOLESTEROL; HOMEOSTASIS; HUMANS; MEMBRANE MICRODOMAINS; PRION DISEASES; PROTEIN FOLDING;

EID: 77956898343     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791591386     Document Type: Article

References (128)

1. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Rev Neurosci 2003; 4: 49-60.
2. Virchow R. Zur cellulose-frage. Arch Pathol Anat Physiol Klin Med 1854; 6: 416-426.
3. Klunk WE; Pettegrew JW, Abraham D.J. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem 1989; 37: 1273-1281.
4. Naiki H, Higuchi K, Hosokawa M, Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem 1989; 177: 244-249.
5. Mattson MP. Impairment of membrane transport and signal transduction systems by amyloidogenic proteins. Methods Enzymol 1999; 309: 733-768.
6. Stefani M. Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity. Neuroscientist 2007; 13: 519-531.
7. Mason RP, Shoemaker WJ, Shajenko L, Chambers TE, Herbette LG. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Aging 1992; 13: 413-419.
8. Koudinov AL, Koudinova NV. Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J Neurol Sci 2005; 229: 233-240.
9. Sjögren M, Mielke M, Gustafson D, Zandi P, Skoog I. Cholesterol and Alzheimer's disease-is there a relation? Mech Ageing Dev 2006;127:138-147.
10. Stefani M, Liguri G. Cholesterol in Alzheimer's Disease: Unresolved Questions. Curr Alzh Res 2009; 6: 15-29.
11. Arispe N, Doh M. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AßP (1-40) and (1-42) peptides. FASEB J 2002; 16: 1526-1536.
12. Forloni G, Terreni L, Bertani I, et al. Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging 2002; 23: 957-976.
13. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev 2007; 8: 128-140.
14. Kojro E, Gimpl G, Lammich S, März W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci USA 2001; 98: 5815-5820.
15. Abad-Rodriguez J, Ledesma MD, Craessaerts K, et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol (2004; 167: 953-960.
16. Crameri A, Biondi E, Kuehnle K, et al. The role of seladin- 1/DHCR24 in cholesterol biosynthesis, APP processing and Aβ generation in vivo. EMBO J 2006; 25: 432-443.
17. Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem 2009; 390: 287-293.
18. Le Lay S, Ferre P, Dugail I. Adipocyte cholesterol balance in obesity. Biochem Soc Trans 2004; 32: 103-106.
19. London E. Insights into lipid raft structure and formation from experiments in model membranes. Curr Opin Struc Biol 2002; 12: 480-486.
20. Ohvo-Rekila H, Ramstedt B, Leppimaki P, Slotte JP. Cholesterol interactions with phospholipids in membranes. Prog Lipid Res 2002; 41: 66-97.
21. Clejan S. In: Methods in Molecular Biology, Phospholipid Signaling Protocols; Bird and Clejan, Eds. New Jersey: Humana Press 1998, Vol. 105: pp. 275-285.
22. Schmitz G, Beuck M, Fischer H, Nowicka G, Robenek H. Regulation of phospholipid biosynthesis during cholesterol influx and high density lipoprotein-mediated cholesterol efflux in macrophages. J Lipid Res 1990; 31: 1741-1752.
23. Ridgway ND, Byers DM, Cook HW, Storey MK. Sphingomyelin and related lipids: structure, occurrence, biosynthesis and analysis. Prog Lipid Res 1999; 38: 337-360.
24. Lucero HA, Robbins PW. Lipid rafts-protein association and the regulation of protein activity. Arch Biochem Biophys 2004; 426: 208-224.
25. Rouvinski A, Gahali-Sassa I, Stavb I, et al. Both raft- and non-raft proteins associate with CHAPS-insoluble complexes: some APP in large complexes. Biochem Biophys Res Com 2003; 308: 750-758.
26. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002; 110: 597-603.
27. Dessi S, Batetta B. In: Cell Growth and Cholesterol Esters; Pani and Dessì Eds. New York, NY, USA: Kluwer Academic/Plenum Publisher 2004; pp 1-10.
28. Dessi S, Batetta B. In: Cell Growth and Cholesterol Esters; Pani and Dessì Eds. New York, NY, USA: Kluwer Academic/Plenum Publisher 2004; pp 25-33.
29. Goldstein JL, Brown MS. Familial hypercholesteroleia: Identification of a defect in the regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci USA 1973; 70: 2804-2808.
30. Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci USA 1974; 71: 788-792.
31. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
32. Nohturfft A, Yabe D, Goldstein JL, Brown MS, Espenshade PJ. Regulated step in cholesterol feedback localized to budding of SCAP from ER membranes. Cell 2000; 102: 315-323.
33. Yang T, Espenshade PJ, Wright ME, et al. Crucial step in cholesterol homeostasis: Sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002; 110: 489-500.
34. Athenstaedt K, Daum G. The life cycle of neutral lipids: synthesis, storage and degradation. Cell Mol Life Sci 2006; 63: 1355-1369.
35. Igarashi M, Osuga J, Isshiki M, et al. Targeting of neutral cholesterol ester hydrolase to the endoplasmic reticulum via its N- terminal sequence. J Lipid Res 2010; 51: 274-285.
36. Prinz W. Cholesterol trafficking in the secretory and endocytic systems. Sem Cell Dev Biol 2002; 13: 197-203.
37. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005; 438: 36-45.
38. Martin S, Parton RG. Lipid droplets: a unified view of a dynamic organelle. Nature Rev Mol Cell Biol 2006; 7: 373-378.
39. Zehmer JK, Huang Y, Peng G, et al. A role for lipid droplets in inter-membrane lipid traffic. Proteomics 2009; 9: 914-921.
40. Kruth HS. Macrophage foam cells and atherosclerosis. Front Biosci 2001; 6: 429-455.
41. Blouin CM, Le LS, Lasnier F, Dugail I, Hajduch E. Regulated association of caveolins to lipid droplets during differentiation of 3T3-L1 adipocytes. Biochem Biophys Res Commun 2008; 376: 331-335.
42. Fujimoto T, Kogo H, Ishiguro K, Tauchi K, Nomura R. Caveolin-2 is targeted to lipid droplets, a new "membrane domain" in the cell. J Cell Biol 2001; 152: 1079-1085.
43. Albrecht C, Viturro EP. The ABCA subfamily-gene and protein structures, functions and associated hereditary diseases. Pflugers Arch 2007; 453: 581-589.
44. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
45. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
46. Selkoe DJ. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 11039-11041.
47. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000; 113: 1857-1870.
48. Esler WP, Wolfe MS. A portrait of Alzheimer secretases-new features and familiar faces. Science 2001; 293: 1449-1454.
49. Nunan J, Small DH. Regulation of APP cleavage by α-, β- and γ- secretases. FEBS Lett 2000; 483: 6-10.
50. Allinson TMJ, Parkin ET, Turner AJ, Hooper NMJ. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 2003; 74: 342-352.
51. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003; 160: 113-123.
52. Harris DA. Cellular biology of prion diseases. Clin Microbiol Rev 1999; 12: 429-444.
53. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 1991; 266: 18217-18223.
54. Campana V, Sarnataro D, Zurzolo C. The highways and byways of prion protein trafficking. Trends Cell Biol 2005; 15: 102-111.
55. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95: 13363-13383.
56. Legname G, DeArmond SJ, Cohen FE; Prusiner SB. (2007) Coll. Biomed. Life Sci. Springer Link, 6, 125-146.
57. Donne DG, Viles JH, Groth DF. Structure of the recombinant full- length hamster prion protein PrP (29-231): the N terminus is highly flexible. Proc Natl Acad Sci USA 1997; 94: 13452-13457.
58. Chiesa R, Harris DA. Prion diseases: what is the neurotoxic molecule? Neurobiol Dis 2001; 8: 743-763.
59. Harris DA, Huber MT, van Dijken P, et al. Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. Biochemistry 1993; 32: 1009-1016.
60. Jimenez-Huete A, Lievens PMJ, Vidal R, et al. Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues. Am J Pathol 1998; 153: 1561-1572.
61. Vincent B, Cisse MA, Sunyach C, Guillot-Sestier MV, Checler F. Regulation of beta APP and PrPc cleavage by alpha-secretase: mechanistic and therapeutic perspectives. Curr Alzheimer Res 2008; 5: 202-211.
62. Hooper NM. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem Soc Trans 2005; 33: 335-338.
63. Kamal A, Stokin GB, Yang Z, Xia CH, Goldstein LS. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 2000; 28: 449-459.
64. Whitaker C, Eckman C, Almeida C, et al. Amyloid-beta degradation: the forgotten half of Alzheimer's disease. J Alzheimer Dis 2003; 5: 491-497.
65. Parkin ET, Watt NT, Hussain I, et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci USA 2007; 104: 11062-11067.
66. Malcolm J, Gains A, LeBlanc AC. Prion protein and prion diseases: the good and the bad. Can J Neurol Sci 2007; 34: 126-145.
67. c in epithelial FRT cells. PLoS ONE 2009; 4(6), e5829.
68. Ledesma MD, Dotti CG. The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system. Biochem Soc Symp 2005; 72: 129-138.
69. Reid PC, Urano Y, Kodama T, Hamakubo T. Alzheimer's Disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 2007; 11: 383-392.
70. Taraboulos, A, Scott M, Semenov A, et al. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 1995; 129: 121-32.
71. Bate C, Salmona M, Diomede L, Williams A. Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem 2004; 279: 14983-14990.
72. Mok SW, Thelen KM, Riemer C, et al. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem Biophys Res Commun 2006; 348: 697-702.
73. Kempster S, Bate C, Williams A. Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport 2006; 18: 479-482.
74. Bate C, Rumbold L, Williams A. Cholesterol synthesis inhibitors protect against platelet-activating factor-induced neuronal damage. J Neuroinflam 2007, 4:5. Doi:10.1186/1742-2094-4-5.
75. Haviv Y, Avrahami D, Ovadia H, et al. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin. Arch Neurol 2008; 65: 762-773.
76. Hwang D, Lee IY, Yoo H, et al. A systems approach to prion disease. Mol Syst Biol 2009; 5:252. Doi:10.1038/msb.2009.10.
77. Sorensen G, Medina S, Parchaliuk D, et al. Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes. BMC Genom 2008; 9:114. Doi:10.1186/1471-2164-9-114.
78. Bach, C.; Gilch S.; Rost R, et al. Prion-induced activation of cholesterogenic gene expression by SREBP2 in neuronal cells. J Biol Chem 2009; 284: 31260-31269.
79. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
80. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006; 129: 2840-2855.
81. Rea TD, Breitner JC, Psaty BM. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol 2005; 62: 1047-1051.
82. Höglund K, Blennow K. Effect of HMG-CoA Reductase Inhibitors on [beta]-Amyloid Peptide Levels: Implications for Alzheimer's Disease. CNS Drugs 2007; 21: 449-462.
83. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007; 69: 878-885.
84. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuro- pathology. Neurology 2008; 70: 1795-1802.
85. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
86. van der Most PJ, Dolga AM, Nijholt IM, Luiten PGM, Eise ULM. Statins: Mechanisms of neuroprotection. Prog Neurobiol 2009; 88: 64-75.
87. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39: 17-23.
88. Wollmer MA, Streffer JR, Tsolaki M, et al. Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. Mol Psychiatry 2003; 8: 635-638.
89. Hutter-Paier B, Huttunen HJ, Puglielli L, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 2004; 44: 227-238.
90. Huttunen HJ, Greco C, Kovacs DM. Knockdown of ACAT-1 reduces amyloidogenic processing of APP. FEBS Lett 2007; 581: 1688-1692.
91. Huttunen HJ, Kovacs DM. ACAT as a drug target for Alzheimer's disease. Neurodegener Dis 2008; 5: 212-214.
92. Sc concentrations in cultured cells. J Gen Virol 2008; 89: 1525-1532.
93. Wahrle SE, Jiang H, Parsadanian M, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008; 118: 671-682.
94. Pani A, Dessì S, Diaz G, et al. Altered cholesterol ester cycle in skin fibroblasts from patients with Alzheimer's disease. J Alzheimer Dis 2009; 18: 829-841.
95. [95] Pani A, Mandas A, Diaz G, et al. Accumulation of neutral lipids in peripheral blood mononuclear cells as a distintive trait of Alzheimer patients and asymptomatic subjects at risk of disease. BMC Med 2009; 7: 66. Doi:10.1186/1741-7015-7-66.
96. Pani A, Norfo C, Abete C, et al. Accumulation of cholesterol esters in ex vivo lymphocytes from scrapie-susceptible sheep and in scrapie-infected mouse neuroblastoma cell lines. Am J Infect Dis 2007; 3: 165-168.
97. Pani A, Abete C, Norfo C, et al. Cholesterol metabolism in brain and skin fibroblasts from sarda breed sheep with scrapie-resistant and scrapie-susceptible genotypes. Am J Infect Dis 2007; 3:143-150.
98. Orrù CD, Abete C, Cannas MD, et al. ACAT, Cav1 and PrP expression in scrapie susceptible and resistant sheep. Cent Eur J Biol 2010; 5: 31-37.
99. Bate B, Tayebi M, Williams A. Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospho- lipase A2 activation. BMC Biol 2008; 6: 8. Doi:10.1186/1741-7007-6-8.
100. Pani A, Norfo C, Abete C, et al. Anti-prion activity of cholesterol esterification modulators: a comparative study in ex vivo sheep fibroblasts and lymphocytes and in mouse neuroblastoma cell lines. Antimicrob Agents Chemother 2007; 51: 4141-4147.
101. Orrù CD, Cannas MD, Vascellari S, et al. In vitro synergistic anti- prion effect of cholesterol ester modulators in combination with chlorpromazine and quinacrine. Cent Eur J Biol 2010; 5: 151-165.
102. Ghaemmaghami S, Phuan PW, Perkins B, et al. Cell division modulates prion accumulation in cultured cells. Proc Natl Acad Sci USA 2007; 104: 17971-17976.
103. Pani A, Dessì S. Cell growth and cholesterol esters. New York: Kluwer Academic/Plenum Publisher 2004.
104. Chang TY, Chang CC, Cheng D. Acyl-coenzyme A:cholesterol acyltransferase. Annu Rev Biochem 1997; 66: 613-638.
105. Buhman KF, Accad M, Farese RV. Mammalian acyl- CoA:cholesterol acyltransferases. Biochim Biophys Acta 2000; 1529: 142-154.
106. Chang TY, Chang CC, Lin S, et al. Roles of acylcoenzyme A:cholesterol acyltransferase-1 and -2. Curr Opin Lipidol 2001; 12: 289-296.
107. Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008; 15: 458-464.
108. Love R. Old drugs to treat new variant Creutzfeldt-Jakob disease. Lancet 2001; 358: 563-574.
109. Stewart LA, Rydzewska LHM, Keogh GF, Knight RSG. Systematic review of therapeutic interventions in human prion disease. Neurology 2008; 70: 1272-1281.
110. Aisen PS. Alzheimer's disease therapeutic research: the path forward. Alzh Res Ther 2009; 1:2. Doi:10.1186/alzrt2
111. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient- preference trial. Lancet Neurol 2009; 8: 334-344.
112. Sim VL, Caughey B. Recent advances in prion chemotherapeutics. Infect Dis Drug Targets 2009; 9: 81-91.
113. Kocisko D, Caughey B, Morrey JD, Race RE. Enhanced antiscrapie effect using combination drug treatment. Antimicrob Agents Chemother 2006; 50: 3447-3449.
114. Klingenstein R, Lober S, Kujala P, et al. Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem 2006; 98: 748-759.
115. Doh-ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000; 74: 4894-4897.
116. Fernø J, Skrede S, Vik-Mo AO, Havic B, Steen VD. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS- related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 2006; 7: 69-80.
117. Vik-Mo AO, Fernø J, Skrede S, Steen VM. Psychotropic drugs up- regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol 2009; 9:10. Doi:10.1186/1471-2210-9-10.
118. Varghese Z, Fernando R, Moorhead JF, Powis SH, Ruan XZ. Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts. Am J Physiol Renal Physiol 2005; 289: 43-48.
119. Butler JD, Banchette-Mackie J, Golden E, et al. Progesterone blocks cholesterol translocation from lysosomes. J Biol Chem 1992; 267: 23797-23805.
120. Debry P, Nash EA, Neklason DW, Metherall JE. Role of multidrug resistance P-glycoproteins in cholesterol esterification. J Biol Chem 1997; 272: 1026-1031.
121. Freeman DA, Romero A. Effects of troglitazone on intracellular cholesterol distribution and cholesterol-dependent cell functions in MA-10 Leydig tumor cells. Biochem Pharmacol 2003; 66: 307-313.
122. Zetterberg H, Blennow K, Hanse E. Amyloid beta and APP as biomarkers for. Alzheimer's disease. Exp Gerontol 2010; 45: 23-29.
123. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004; 25: 641-650.
124. Sonnen JA, Montin KS, Quinn JF, et al. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 2008; 7: 704-714.
125. Alegret M, Llaverias G, Silvestre JS. Acyl coenzyme A:cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs. Methods Find Exp Clin Pharmacol 2004; 26: 563-586.
126. Dolphin GT, Chierici S, Ouberai M, Dumy P, Garcia J. A multimeric quinacrine conjugate as a potential inhibitor of Alzheimer's β-amyloid fibril formation. ChemBioChem 2008; 9: 952-963.
127. CJD (Creutzfeldt-Jakob disease) quinacrine study. Available at: http://clinicaltrials.gov/ct2/show/NCT00183092 [accessed March 4, 2009].
128. Sato T, Hanyu H, Hirao K, et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2009; Nov 16 [Epub ahead of print] Doi:10.1016/jneurobiolaging. 2009.10.009.